Literature DB >> 15146248

Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.

Sivasubramanian Baskar1, Carol B Kobrin, Larry W Kwak.   

Abstract

The clonotypic surface Ig receptor expressed by malignant B cells, idiotype, is a tumor-specific antigen and an attractive target for active immunotherapy. While Ab's specific for tumor idiotype have been well described in patients with B cell malignancies, the precise antigenic epitopes in human idiotype recognized by autologous T cells remain largely unknown. We report here that T cell lines generated from lymphoma patients actively immunized with idiotype protein specifically recognized multiple, unique immunodominant epitopes in autologous tumor idiotype. Synthetic peptides corresponding to hypervariable, but not framework, regions of Ig heavy chain specifically stimulated CD4(+) and CD8(+) T cells to proliferate and secrete proinflammatory cytokines in an MHC-associated manner. Detailed analysis revealed a minimal determinant of an immunodominant epitope, comprising critical residues at the amino terminus that may be a product of somatic hypermutation. Association of idiotype-specific T cell responses with previously documented molecular remissions in idiotype-vaccinated patients suggests that the newly identified T cell epitopes may be clinically relevant. Such antigenic epitopes may serve as candidates for novel peptide-vaccine strategies, and as tools to selectively expand tumor antigen-specific T cells for adoptive immunotherapy and for monitoring T cell immunity in vaccinated patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146248      PMCID: PMC406527          DOI: 10.1172/JCI20312

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies.

Authors:  A Trojan; J L Schultze; M Witzens; R H Vonderheide; M Ladetto; J W Donovan; J G Gribben
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

3.  Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia.

Authors:  M R Rezvany; M Jeddi-Tehrani; H Rabbani; U Rudén; L Hammarström; A Osterborg; H Wigzell; H Mellstedt
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

4.  Somatically mutated regions of immunoglobulin on human B-cell lymphomas code for peptides that bind to autologous major histocompatibility complex class I, providing a potential target for cytotoxic T cells.

Authors:  C S Gricks; E Rawlings; L Foroni; J A Madrigal; P L Amlot
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

5.  Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.

Authors:  Y J Wen; B Barlogie; Q Yi
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

6.  Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.

Authors:  A Heiser; M A Maurice; D R Yancey; D M Coleman; P Dahm; J Vieweg
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

7.  Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.

Authors:  V Dutoit; V Rubio-Godoy; P Y Dietrich; A L Quiqueres; V Schnuriger; D Rimoldi; D Liénard; D Speiser; P Guillaume; P Batard; J C Cerottini; P Romero; D Valmori
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

8.  Presence and potent immunosuppressive role of interleukin-10 in malignant pleural effusion due to lung cancer.

Authors:  H Yanagawa; E Takeuchi; Y Suzuki; Y Ohmoto; H Bando; S Sone
Journal:  Cancer Lett       Date:  1999-02-08       Impact factor: 8.679

9.  Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.

Authors:  S Titzer; O Christensen; O Manzke; H Tesch; J Wolf; B Emmerich; C Carsten; V Diehl; H Bohlen
Journal:  Br J Haematol       Date:  2000-03       Impact factor: 6.998

Review 10.  Human tumor antigens for cancer vaccine development.

Authors:  R F Wang; S A Rosenberg
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

View more
  20 in total

1.  Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Authors:  Stephen J Schuster; Sattva S Neelapu; Barry L Gause; John E Janik; Franco M Muggia; Jon P Gockerman; Jane N Winter; Christopher R Flowers; Daniel A Nikcevich; Eduardo M Sotomayor; Dean S McGaughey; Elaine S Jaffe; Elise A Chong; Craig W Reynolds; Donald A Berry; Carlos F Santos; Mihaela A Popa; Amy M McCord; Larry W Kwak
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.

Authors:  Jinsheng Weng; Soung-Chul Cha; Satoko Matsueda; Gheath Alatrash; Michael S Popescu; Qing Yi; Jeffrey J Molldrem; Michael Wang; Sattva S Neelapu; Larry W Kwak
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

Review 3.  Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.

Authors:  Maurizio Bendandi
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 4.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

5.  Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.

Authors:  Tetsuya Nishida; Michael Hudecek; Ana Kostic; Marie Bleakley; Edus H Warren; David Maloney; Rainer Storb; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

6.  Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.

Authors:  Susana Inoges; Ascension Lopez-Diaz de Cerio; Helena Villanueva; Fernando Pastor; Elena Soria; Maurizio Bendandi
Journal:  World J Clin Oncol       Date:  2011-06-10

7.  A simple, clinically relevant therapeutic vaccine shows long-term protection in an aggressive, delayed-treatment B lymphoma model.

Authors:  Pallab Pradhan; Jardin Leleux; Jiaying Liu; Krishnendu Roy
Journal:  JCI Insight       Date:  2017-11-16

8.  Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.

Authors:  Sandra Iurescia; Daniela Fioretti; Pasquale Pierimarchi; Emanuela Signori; Manuela Zonfrillo; Giancarlo Tonon; Vito M Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-04-27

9.  Profound impairment of adaptive immune responses by alkylating chemotherapy.

Authors:  Adam J Litterman; David M Zellmer; Karen L Grinnen; Matthew A Hunt; Arkadiusz Z Dudek; Andres M Salazar; John R Ohlfest
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

Review 10.  Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.

Authors:  Elena Muraro; Debora Martorelli; Riccardo Dolcetti
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.